Back

Equal performance of the subcutaneous and transvenous implantable cardioverter defibrillator across all age groups in the PRAETORIAN trial

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Subcutaneous and extravascular defibrillators: already mainstream? Device Treatment ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Miss Shari Pepplinkhuizen

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Defibrillation success with a second generation intercostal extravascular ICD lead and commercially available left pectoral pulse generator
Doctor M. Burke (Chicago, US)
Abstract Slides Video
Presentation thumbnail
A comparative analysis of conduction system pacing and biventricular pacing in patients undergoing atrioventricular node ablation: a systematic review and meta-analysis
Doctor H. Eldeeb (Bristol, GB)
Abstract Slides Video
Presentation thumbnail
Sex differences in shocks and device-related complications in subcutaneous implantable-cardioverter defibrillator patients
Ms J. De Veld (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Antithrombotic therapy and the risk of pocket hematoma after subcutaneous implantable cardioverter-defibrillator implantation
Miss S. Pepplinkhuizen (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
long term follow up of Implantable Cardioverter Defibrillators (ICD) in hypertrophic cardiomyopathy: is subcutaneous the way forward?
Mr C. Monkhouse (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Subcutaneous and extravascular defibrillators: already mainstream?

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Subcutaneous versus transvenous implantable cardioverter-defibrillator therapy: real world data from a Portuguese cohort
thumbnail
Congress Presentation
Sex differences in shocks and device-related complications in subcutaneous implantable-cardioverter defibrillator patients
thumbnail
Congress Presentation
long term follow up of Implantable Cardioverter Defibrillators (ICD) in hypertrophic cardiomyopathy: is subcutaneous the way forward?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources